ArticleResearch and practice in thrombosis and haemostasis2025
A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection.Signal transduction and targeted therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We have reported that trivalent and tetravalent nanobodies against glycoprotein (GP)VI, C-type lectin-like receptor (CLEC)-2, and platelet endothelial aggregation receptor (PEAR)1 stimulate powerful aggregation and adenosine triphosphate secretion in human platelets. Objectives: This study aimed to evaluate changes in platelet surface GPs elicited by activation of GPVI, CLEC-2, and PEAR1 using trivalent and tetravalent nanobodies. Methods: The effect of the crosslinked nanobodies on P-selectin was measured in whole blood and washed platelets with and without secondary mediator inhibitors using classical flow cytometry and on 16 platelet surface GPs in whole blood using multispectral flow cytometry. Results: Trivalent nanobodies to GPVI and CLEC-2 stimulated modest (<60% of collagen-related peptide) expression of P-selectin in whole blood (10-fold dilution) and washed platelets (2 × 10 Conclusion: Tetravalent nanobodies to GPVI and CLEC-2 stimulate powerful activation of platelets at low nanomolar concentrations in flow cytometry. In contrast, trivalent nanobodies are partial agonists. The defined stoichiometry of the nanobodies will aid development of standardized platelet flow cytometry assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.